Shattuck Labs (STTK) to Release Earnings on Thursday

Shattuck Labs (NASDAQ:STTK) will likely be posting its quarterly earnings results before the market opens on Thursday, March 6th. Analysts expect Shattuck Labs to post earnings of ($0.38) per share and revenue of $1.00 million for the quarter.

Shattuck Labs Stock Down 24.6 %

Shares of NASDAQ:STTK opened at $1.44 on Thursday. The stock has a market cap of $68.75 million, a PE ratio of -0.94 and a beta of 1.70. The company’s fifty day moving average is $1.23 and its 200 day moving average is $1.82. Shattuck Labs has a 52 week low of $0.94 and a 52 week high of $11.76.

Wall Street Analyst Weigh In

A number of equities analysts recently commented on the stock. Needham & Company LLC reiterated a “hold” rating on shares of Shattuck Labs in a research report on Thursday, November 14th. HC Wainwright restated a “neutral” rating on shares of Shattuck Labs in a research report on Friday, November 15th. Four equities research analysts have rated the stock with a hold rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Hold” and an average price target of $8.67.

Insider Buying and Selling at Shattuck Labs

In other news, Director Redmile Group, Llc acquired 133,371 shares of the firm’s stock in a transaction on Wednesday, December 4th. The shares were purchased at an average price of $1.25 per share, for a total transaction of $166,713.75. Following the completion of the transaction, the director now owns 5,539,724 shares of the company’s stock, valued at $6,924,655. The trade was a 2.47 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Corporate insiders own 10.50% of the company’s stock.

Shattuck Labs Company Profile

Shattuck Labs, Inc, a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers.